Paving the Way for Diversity in Clinical Trials

photo of lab researchers

Hala Borno, MD, assistant professor of medicine, Division of Oncology and Hematology, University of California, San Francisco

Jamie Freedman, head of U.S. medical affairs, Genentech.

Jennifer Jones-McMeans, PhD, director of global clinical affairs, Abbott Pharmaceuticals.

Marya Shegog, PhD, health equity and diversity coordinator, Lazarex Cancer Foundation.

Andrea Denicoff, registered nurse and nurse consultant, National Cancer Institute; chief of clinical trials operations, NCI’s National Clinical Trials Network.

‘Lola Fashoyin-Aje, MD, deputy division director and associate director, science and policy to address disparities, Oncology Center of Excellence, FDA.

Keanna Ghazvini, spokesperson, Pfizer Pharmaceuticals.

FDA: “Drug Trials Snapshots: NINLARO.”

National Cancer Institute: “NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research,” “Inclusion of Women and Minorities as Participants in Research Involving Human Subjects,” “Cancer Disparities.” “ Background.”

Lazarex Cancer Foundation.

Genentech Biotechnology Company.

Abbott Laboratories: “Abbott Announces Start Of Trial To Evaluate The New Espri Btk Drug-Eluting Resorbable Scaffold.”

Pfizer Pharmaceuticals.

American Cancer Society.

American Society of Clinical Oncology.

Contemporary Clinical Trials: “Does the COVID-19 outbreak identify a broader need for an urgent transformation of cancer clinical trials research?”

The New York Times: “Clinical Trials Are Moving Out of the Lab and Into People’s Homes.”

Massey Cancer Center, Virginia Commonwealth University: “First Lady Jill Biden visits Massey to discuss cancer disparities and community engaged research.”

ProPublica: “Black Patients Miss Out On Promising Cancer Drugs.”

Leave a Reply

Your email address will not be published. Required fields are marked *

Main Menu